Visakhapatnam: Drug repurposing is emerging as a promising strategy for tackling drug-resistant and metastatic cancers.

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Biogen BIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the ...

The new report examines Abbreviated New Drug Application (ANDA) cases and the Orange Book-listed products at issue throughout ...

CHATHAM, N.J. - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a biopharmaceutical company, has announced a 1-for-100 reverse stock split of its common stock, set to take effect as trading opens ...

IRA has unintended consequences on investment landscape for small- and large-molecule drugs stifling the development of new ...

Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...

The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...